AL
Alma Yesodot Ltd.
KVSR | TA
Overview
Corporate Details
- ISIN(s):
- IL0011731457
- LEI:
- Country:
- Israel
- Address:
- HaBarzel 3, 6971005 Tel Aviv - Jaffa
- Website:
- https://www.almayesodot.co.il/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Kvasir focuses on developing innovative medical devices and diagnostic technologies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-04-24 17:08 |
Regulatory News Service
Opening of Trading on April 27 2025-ALMA YESODOT B1
|
Hebrew (modern) | 118.8 KB | ||
| 2025-04-23 11:59 |
Regulatory News Service
Identifying Details of New Security-ALMA YESODOT B1
|
Hebrew (modern) | 87.5 KB | ||
| 2024-11-05 15:46 |
Regulatory News Service
Changes in the company's name and security, effective as of November 7, 2024
|
Hebrew (modern) | 108.5 KB | ||
| 2024-10-29 18:37 |
Regulatory News Service
The sector classification of the company will be changed, as of October 31, 202…
|
Hebrew (modern) | 121.3 KB | ||
| 2024-10-29 17:20 |
Regulatory News Service
Base price of 1 agora and unlimited price fluctuation
|
Hebrew (modern) | 90.8 KB | ||
| 2023-05-22 23:20 |
Report Publication Announcement
Frost and Sullivan is terminating coverage , following the completion of its co…
|
Hebrew (modern) | 174.5 KB | ||
| 2023-05-22 23:20 |
Pre-Annual General Meeting Information
Frost and Sullivan is terminating coverage , following the completion of its co…
|
Russian | 46.0 KB | ||
| 2023-03-23 21:00 |
Investor Presentation
Analysis update following financial report- price target is updated to NIS 22.7
|
English | 1.2 MB | ||
| 2023-03-23 21:00 |
Legal Proceedings Report
Analysis update following financial report- price target is updated to NIS 22.7
|
Russian | 71.0 KB | ||
| 2022-12-11 20:40 |
Investor Presentation
Analysis update following financial report- price target is updated to NIS 32.9…
|
English | 1.2 MB | ||
| 2022-12-11 20:40 |
Business and Financial Review
Analysis update following financial report- price target is updated to NIS 32.9…
|
Russian | 67.3 KB | ||
| 2022-08-30 20:47 |
Investor Presentation
Analysis update report ,target price is at 47.6NIS
|
English | 1.2 MB | ||
| 2022-08-30 20:47 |
Business and Financial Review
Analysis update report ,target price is at 47.6NIS
|
Russian | 63.9 KB | ||
| 2022-08-18 16:58 |
Investor Presentation
Presentation
|
English | 3.0 MB | ||
| 2022-08-18 16:58 |
Pre-Annual General Meeting Information
Presentation
|
Russian | 42.7 KB |
Automate Your Workflow. Get a real-time feed of all Alma Yesodot Ltd. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Alma Yesodot Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Alma Yesodot Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Develops CAR-T therapies for blood cancers, autoimmune disorders, and viral infections.
United Kingdom
HEMO
United Kingdom
HEMO
Microbiome biotech using analysis for personalized probiotics, LBPs, and full CDMO services.
South Korea
376270
South Korea
376270
A vertically integrated supplier of medical cannabis raw material for the Polish market.
Poland
HMP
Poland
HMP
Developing disease-modifying therapies for neurodegenerative conditions like Parkinson's disease.
Finland
HRTIS
Finland
HRTIS
Develops and commercializes therapies for acute care and oncology to manage pain and nausea.
United States of America
HRTX
United States of America
HRTX
South Korea
106190
Develops & markets affordable generic & specialty medicines for markets in NA, MENA, & Europe.
United Kingdom
HIK
United Kingdom
HIK
A global leader in transdermal drug delivery systems for OTC and prescription pain relief.
Japan
4530
Japan
4530
Develops custom enzymes & microbiome solutions for diagnostics, nutrition, and cosmetic markets.
South Korea
187420
South Korea
187420
A diversified group in pharma, shipbuilding, life sciences, and professional advisory services.
South Korea
028300
South Korea
028300